Search

everythinglearnresearchcommunity

for

Search:↓

Erectile dysfunction is increasingly common in men under 40, with many physical and psychological causes, and various treatment options available.

Polycystic Ovary Syndrome likely starts in childhood and may be genetic and influenced by early hormone exposure.

Hair loss from Telogen Effluvium usually gets better within 6 months after addressing the cause.

Certain metabolites are lower in women with PCOS and could be potential markers for the condition.

Greek women with PCOS have a higher risk of metabolic syndrome and are more likely to be overweight compared to healthy controls.

Hirsutism is common body hair growth due to genetics and hormones, and while not a disease, it can be distressing; virilisation includes hirsutism with other male traits and needs medical attention.

Certain gene variants in estrogen receptors are linked to polycystic ovary syndrome, mainly affecting metabolism, in Tunisian women.

The review suggests a comprehensive approach to treat hirsutism, focusing on hair removal, medication, and managing emotional effects.

Telogen Effluvium is a common hair loss condition that can be short-term or long-lasting and is often caused by stress, illness, or nutritional issues.

A very low-calorie ketogenic diet led to weight loss and improved metabolic and hormonal health in obese men, with better sperm motility.

Skin symptoms can indicate endocrine disorders and have various treatments.

Excessive hair growth in women, often from high androgen levels, is usually caused by PCOS, and can be treated with hair removal, medication, and possibly weight loss.

The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.

Myo-inositol may be more effective than metformin for inducing ovulation in women with PCOS.

Greek women with classic PCOS are more likely to have metabolic syndrome and insulin resistance than those with newer PCOS types.

The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.

Hormone therapy for trans individuals is effective and generally safe in the short term.

Metformin is effective for treating excessive hair growth in women with PCOS and may work better than the standard treatment in some ways.

Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.

Most women with PCOS have high levels of male hormones, and free testosterone is the best marker for this.

Oral spironolactone's effectiveness for adult female acne is not well-supported by strong evidence.

The conclusion is that early diagnosis and a multi-system treatment approach are crucial for managing PCOS and its associated health risks.

Women with PCOS have more body fat and thicker fat layers in certain abdominal areas than women without PCOS.

Eating 500 fewer calories a day and making lifestyle changes can improve PCOS symptoms and reduce diabetes risk; more research is needed on its causes and treatments.

Minoxidil promotes hair growth in women with early-stage alopecia.

Taking low-dose spironolactone and metformin together works better for PCOS symptoms than either drug alone.

Finasteride effectively reduces hair growth in women with idiopathic hirsutism, but requires careful contraception during treatment.

Polycystic ovarian shape is a genetic sign of PCOS and its hormonal and metabolic features can be inherited.